This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alemzadeh, R. Articles by Slonim, A. E. Search for Related Content PubMed PubMed Citation Articles by Alemzadeh, R. Articles by Slonim, A. E.

Beneficial Effect of Diazoxide in Obese Hyperinsulinemic Adults¹

Department of Pediatrics (R.A., G.L., L.U., P.S.), University of Tennessee, Graduate School of Medicine, Knoxville, Tennessee 37920; and Department of Pediatrics (A.E.S.), Northshore University Hospital-New York University, School of Medicine, Manhasset, New York 11030

Address all correspondence and requests for reprints to: Ramin Alemzadeh, M.D., Division of Pediatric Endocrinology, Metabolism and Nutrition, University of Tennessee Medical Center, 1924 Alcoa Highway, U-113, Knoxville, Tennessee 37920. E-mail: ralemzad{at}mc.utmck.edu

Hyperinsulinemia, insulin resistance, and increased adipose tissue are hallmarks of the obesity state in both humans and experimental animals. The role of hyperinsulinemia as a possible preceding event in the development of obesity has been proposed. We previously demonstrated that administration of diazoxide (DZ), an inhibitor of insulin secretion, to obese hyperinsulinemic Zucker rats resulted in less weight gain, enhanced insulin sensitivity, and improved glucose tolerance. Assuming that hyperinsulinemia plays a major role in the development of human obesity, then its reversal should have therapeutic potential. To test this hypothesis, we conducted a randomized placebo-controlled trial in 24 hyperinsulinemic adults [body mass index (BMI) > 30 kg/m²]. All subjects were placed on a low-calorie (1260 for females and 1570 for males) Optifast (Sandoz, Minneapolis, MN) diet. After an initial 1-week lead-in period, 12 subjects (mean ± SE for age and BMI, 31 ± 1 and 40 ± 2, respectively) received DZ (2 mg/kg BW·day; maximum, 200 mg/day, divided into 3 doses) for 8 weeks; and 12 subjects (mean ± SE for age and BMI, 28 ± 1 and 43 ± 1, respectively) received placebo. Compared with the placebo group, DZ subjects had greater weight loss (9.5 ± 0.69% vs. 4.6 ± 0.61%, P < 0.001), greater decrease in body fat (P < 0.01), greater increase in fat-free mass to body fat ratio (P < 0.01), and greater attenuation of acute insulin response to glucose (P < 0.01). However, there was no significant difference in insulin sensitivity and glucose effectiveness, as determined by the insulin-modified iv glucose tolerance test (Bergman’s minimal model) and no significant difference in glycohemoglobin values. Conclusion: 8 weeks treatment with DZ had a significant antiobesity effect in hyperinsulinemic obese adults without inducing hyperglycemia.

This article has been cited by other articles:

				J.-P. Chaput, A. Tremblay, E. B Rimm, C. Bouchard, and D. S Ludwig A novel interaction between dietary composition and insulin secretion: effects on weight gain in the Quebec Family Study Am. J. Clinical Nutrition, February 1, 2008; 87(2): 303 - 309. [Abstract] [Full Text] [PDF]

				M. B. Zemel The Role of Dairy Foods in Weight Management J. Am. Coll. Nutr., December 1, 2005; 24(suppl_6): 537S - 546S. [Abstract] [Full Text] [PDF]

				L. E. Fridlyand and L. H. Philipson Does the Glucose-Dependent Insulin Secretion Mechanism Itself Cause Oxidative Stress in Pancreatic {beta}-Cells? Diabetes, August 1, 2004; 53(8): 1942 - 1948. [Abstract] [Full Text] [PDF]

				M. B. Zemel Mechanisms of Dairy Modulation of Adiposity J. Nutr., January 1, 2003; 133(1): 252S - 256. [Abstract] [Full Text] [PDF]

				K. E. Cosgrove, M.-H. Antoine, A. T. Lee, P. D. Barnes, P. de Tullio, P. Clayton, R. McCloy, P. De Lonlay, C. Nihoul-Fekete, J.-J. Robert, et al. BPDZ 154 Activates Adenosine 5'-Triphosphate-Sensitive Potassium Channels: In Vitro Studies Using Rodent Insulin-Secreting Cells and Islets Isolated from Patients with Hyperinsulinism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4860 - 4868. [Abstract] [Full Text] [PDF]

				A. E. Pontiroli, P. Pizzocri, M. C. Librenti, P. Vedani, M. Marchi, E. Cucchi, C. Orena, M. Paganelli, M. Giacomelli, G. Ferla, et al. Laparoscopic Adjustable Gastric Banding for the Treatment of Morbid (Grade 3) Obesity and its Metabolic Complications: A Three-Year Study J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3555 - 3561. [Abstract] [Full Text] [PDF]

				M. Dabrowski, F. M. Ashcroft, R. Ashfield, P. Lebrun, B. Pirotte, J. Egebjerg, J. Bondo Hansen, and P. Wahl The Novel Diazoxide Analog 3-Isopropylamino-7-Methoxy-4H-1,2,4-Benzothiadiazine 1,1-Dioxide Is a Selective Kir6.2/SUR1 Channel Opener Diabetes, June 1, 2002; 51(6): 1896 - 1906. [Abstract] [Full Text] [PDF]

				R. S. Surwit, T. M. Dixon, A. E. Petro, K. W. Daniel, and S. Collins Diazoxide Restores {beta}3-Adrenergic Receptor Function in Diet-Induced Obesity and Diabetes Endocrinology, October 1, 2000; 141(10): 3630 - 3637. [Abstract] [Full Text] [PDF]

				M. F McCarty The alcohol paradox Am. J. Clinical Nutrition, November 1, 1999; 70(5): 940 - 941. [Full Text]

				H. SHI, N. MOUSTAID-MOUSSA, W. O. WILKISON, and M. B. ZEMEL Role of the sulfonylurea receptor in regulating human adipocyte metabolism FASEB J, October 1, 1999; 13(13): 1833 - 1838. [Abstract] [Full Text]